India, June 22 -- Harbour BioMed announced that it has collaborated with Otsuka Pharmaceutical Co., Ltd. to advance BCMAxCD3 bispecific T-cell engagers for the treatment of autoimmune diseases.
As per the terms of the agreement, Otsuka is granted an exclusive license to develop, manufacture, and commercialize HBM7020, a BCMAxCD3 bispecific T-cell engager globally, excluding Greater China (Mainland China, Hong Kong, Macau and Taiwan). In return, Harbour BioMed will receive a total of $47 million in upfront and near-term payments. The company is also eligible for additional payments of up to $623 million upon the achievement of specified development and commercial milestones, as well as tiered royalties on future net sales.
For More Such He...